<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294225</url>
  </required_header>
  <id_info>
    <org_study_id>MC1931</org_study_id>
    <secondary_id>NCI-2020-01062</secondary_id>
    <secondary_id>MC1931</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>P50CA116201</secondary_id>
    <nct_id>NCT04294225</nct_id>
  </id_info>
  <brief_title>Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer</brief_title>
  <official_title>Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well anastrozole and letrozole after surgery work in treating&#xD;
      patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole, may stop&#xD;
      the growth of tumor cells by decreasing the amount of estrogen made by the body. Giving&#xD;
      anastrozole and letrozole after surgery may prevent breast cancer from coming back&#xD;
      (recurrence).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate the proportion of women who have adequate estrone (E1) and estradiol (E2)&#xD;
      suppression after 8-10 weeks of adjuvant anastrozole 10 mg once daily (ANA10) having had&#xD;
      inadequate E1 and E2 suppression after 8-10 weeks of standard dose anastrozole 1 mg once&#xD;
      daily (ANA1).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the proportion of women with elevated E1 and E2 levels after 8-10 weeks of&#xD;
      adjuvant ANA1.&#xD;
&#xD;
      II. To estimate the proportion of women with elevated E1 and E2 levels after 8-10 weeks of&#xD;
      adjuvant ANA1 whose E1 and E2 levels remain elevated after 8-10 weeks of adjuvant ANA10.&#xD;
&#xD;
      III. To examine the toxicity profile of ANA1 over the 8-10 weeks of treatment, ANA10 over the&#xD;
      8-10 weeks of treatment, and letrozole over the 8-10 weeks of treatment.&#xD;
&#xD;
      IV. To examine concentrations of anastrozole at both the ANA1 and ANA10 dose levels.&#xD;
&#xD;
      V. To examine E1 and E2 concentrations, as well as letrozole drug levels, in patients&#xD;
      receiving letrozole (following ANA10).&#xD;
&#xD;
      VI. To bank deoxyribonucleic acid (DNA) for examination of single-nucleotide polymorphism&#xD;
      (SNP)-set(s) determined in the ongoing Mayo Clinic Breast Cancer Specialized Program of&#xD;
      Research Excellence (SPORE) Project 4.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To examine association between clinical variables such as age, age at menopause, body mass&#xD;
      index (BMI), receipt of chemotherapy, chemotherapy regimen, and dose on E1 and E2 levels&#xD;
      after 8-10 weeks of ANA10.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive anastrozole orally (PO) once daily (QD) for 56-70 days (8-10 weeks).&#xD;
      Patients with E1 &gt;= 1.3 pg/ml and E2 &gt;= 0.5 pg/ml continue to receive anastrozole PO QD for&#xD;
      another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks.&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estrogen suppression rate</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Point and interval estimates for the estrogen suppression rate with anastrozole 10 mg daily for 8-10 weeks will be constructed using the properties of the binomial distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of estrone (E1) and estradiol (E2) concentrations</measure>
    <time_frame>After treatment of anastrozole 10 mg once daily and letrozole</time_frame>
    <description>Descriptive statistics will be used. The percent change in E1 and E2 concentrations from pre-AI levels will be determined and graphically depicted using spider plots.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Anatomic Stage I Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IA Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IB Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage II Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIA Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIB Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage III Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIA Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIB Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIC Breast Cancer AJCC v8</condition>
  <condition>Early-Stage Breast Carcinoma</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <condition>Prognostic Stage I Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IA Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IB Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage II Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIA Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIB Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage III Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIA Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIB Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIC Breast Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (anastrozole, letrozole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive anastrozole PO QD for 56-70 days (8-10 weeks). Patients with E1 &gt;= 1.3 pg/ml and E2 &gt;= 0.5 pg/ml continue to receive anastrozole PO QD for another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (anastrozole, letrozole)</arm_group_label>
    <other_name>Anastrazole</other_name>
    <other_name>Arimidex</other_name>
    <other_name>ICI D1033</other_name>
    <other_name>ICI-D1033</other_name>
    <other_name>ZD-1033</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (anastrozole, letrozole)</arm_group_label>
    <other_name>CGS 20267</other_name>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  REGISTRATION-INCLUSION CRITERIA&#xD;
&#xD;
          -  Disease characteristics:&#xD;
&#xD;
               -  Histological confirmation of invasive breast carcinoma&#xD;
&#xD;
               -  Stage I-III breast cancer&#xD;
&#xD;
               -  Estrogen receptor (ER) positive disease according to American Society of Clinical&#xD;
                  Oncology (ASCO)/College of American Pathologists (CAP) guidelines as ER &gt;= 1%&#xD;
                  positive nuclear staining&#xD;
&#xD;
          -  Completion of all planned cancer treatments prior to registration:&#xD;
&#xD;
               -  Surgical resection of breast and nodal surgery; (NOTE: Reconstructive surgery&#xD;
                  does not have to be completed)&#xD;
&#xD;
               -  Adjuvant radiation therapy, if needed&#xD;
&#xD;
               -  Neoadjuvant and/or adjuvant chemotherapy, if needed&#xD;
&#xD;
          -  Post-menopausal defined as&#xD;
&#xD;
               -  Age &gt;= 60 and amenorrhea &gt; 12 consecutive months OR&#xD;
&#xD;
               -  Previous bilateral oophorectomy OR&#xD;
&#xD;
               -  Age &lt; 60 and amenorrhea &gt; 12 consecutive months and documented follicle&#xD;
                  stimulating hormone (FSH) level within post-menopausal range according to&#xD;
                  institutional standard&#xD;
&#xD;
                    -  NOTE: Patients who did not meet these criteria at time of diagnosis and&#xD;
                       received pre-operative (neoadjuvant) or post-operative (adjuvant)&#xD;
                       chemotherapy will not be allowed to participate&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.0 g/dL (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3 (obtained =&lt; 14 days prior to&#xD;
             registration)&#xD;
&#xD;
          -  Platelet count &gt;= 70,000/mm^3 (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) (obtained =&lt; 14 days prior to&#xD;
             registration)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate transaminase (AST) =&lt; 3 x ULN (obtained&#xD;
             =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Ability to swallow oral medication&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Willingness to provide mandatory blood specimens for correlative research&#xD;
&#xD;
          -  Willing to return to enrolling institution for follow-up (during the Active Monitoring&#xD;
             Phase of the study)&#xD;
&#xD;
          -  RE-REGISTRATION-INCLUSION CRITERIA&#xD;
&#xD;
          -  Confirmation that baseline blood sample was drawn and submitted&#xD;
&#xD;
          -  Blood estrogen levels after cycle 1 anastrozole (ANA1) must meet the following&#xD;
             criteria:&#xD;
&#xD;
               -  E1 &gt;= 1.3 pg/ml, AND&#xD;
&#xD;
               -  E2 &gt;= 0.5 pg/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  REGISTRATION-EXCLUSION CRITERIA&#xD;
&#xD;
          -  Pre-menopausal women receiving ovarian function suppression (goserelin, leuprolide,&#xD;
             etc.)&#xD;
&#xD;
          -  Stage IV (metastatic) breast cancer&#xD;
&#xD;
          -  HER2 positive breast cancer as defined by&#xD;
&#xD;
               -  HER2 immunohistochemistry (IHC) &gt;= 3+&#xD;
&#xD;
               -  HER2/CEP17 &gt;= 2.0&#xD;
&#xD;
               -  HER2/CEP17 &lt; 2.0 and average HER2 copy number of &gt;= 6.0 signals/cell&#xD;
&#xD;
          -  Prior endocrine therapy for this breast cancer. Exceptions:&#xD;
&#xD;
               -  Pre-operative aromatase therapy (anastrozole, letrozole, or exemestane) and last&#xD;
                  treatment was &gt;= 4 weeks prior to registration OR&#xD;
&#xD;
               -  Pre-operative tamoxifen therapy and last treatment was &gt;= 12 weeks prior to&#xD;
                  registration&#xD;
&#xD;
          -  Currently receiving any of the following cancer-directed therapies:&#xD;
&#xD;
               -  Radiation therapy&#xD;
&#xD;
               -  Systemic therapy such as chemotherapy (standard or investigational)&#xD;
&#xD;
          -  Bisphosphonate therapy started &lt; 4 weeks prior to registration&#xD;
&#xD;
               -  NOTE: If patient is currently on bisphosphonate therapy she must be on stable&#xD;
                  dose for &gt;= 4 weeks prior to registration. Patients not currently taking&#xD;
                  bisphosphonates will be allowed to start bisphosphonate therapy after completion&#xD;
                  of anastrozole (1 mg and 10 mg daily [if given]). Information regarding&#xD;
                  bisphosphonate therapy will be collected&#xD;
&#xD;
          -  Current use of systemic or topical exogenous estrogen or progesterone (menopausal&#xD;
             hormone replacement therapy [HRT])&#xD;
&#xD;
          -  Prior ovarian function suppression (leuprolide, goserelin, etc.)&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  History of contralateral ductal carcinoma in situ (DCIS) or invasive breast cancer&#xD;
&#xD;
               -  NOTE: Exception allowed if&#xD;
&#xD;
                    -  Patient did not receive adjuvant endocrine therapy OR&#xD;
&#xD;
                    -  Patient received adjuvant endocrine therapy but has been off treatment for&#xD;
                       at least 6 months prior to registration&#xD;
&#xD;
          -  Concurrent active malignancy or history of malignancy =&lt; 3 years prior to registration&#xD;
&#xD;
               -  NOTE: Exceptions allowed for successfully treated cervical carcinoma in situ,&#xD;
                  lobular carcinoma in situ of the breast, papillary thyroid cancer, or&#xD;
                  non-melanoma skin cancer&#xD;
&#xD;
          -  Prior prevention therapy with an aromatase inhibitor or a selective estrogen receptor&#xD;
             modulator (SERM). Exception: Therapy with a SERM (tamoxifen or raloxifene) is allowed&#xD;
             if patient has been off treatment for &gt;= 6 months prior to registration&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tufia C Haddad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Brenda J. Ernst, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referal Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Alvaro Moreno-Aspitia, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clincial Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Tufia C. Haddad, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

